NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
13/02/2024
Voltar para busca
Dado oficial do USPTO
SYNTHETIC BIOPSY
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
SYNTHETIC BIOPSY
ST13
US500000090700876Classe
5, 44
Pedido
90700876
Registro
7305215
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
13/02/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 44
Data de depósito
10/05/2021
Data de registro
13/02/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
13/02/2024
Última transação
13/02/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
04/01/2023
Primeiro uso no comércio
24/01/2023
Código do desenho
4
Tipo de titular
03
Localização do titular
South San Francisco, CA
Examinador
DAWE III, BILL
Unidade examinadora
L80
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Earli Inc.
Representantes
Ted D. Karr BERKELEY LAW & TECHNOLOGY GROUP, LLP
Classificação técnica
Classes Nice
Classe 5Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medical products for human use that trigger expression or activation in the human body of a biomarkercompound or body response useable for prevention of diseasescancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarkercompound or body response useable for detection of diseasescancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarkercompound or body response useable for localization of diseasescancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarkercompound or body response useable for therapy of diseasescancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarkercompound or body response useable for prevention of diseasescancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarkercompound or body response useable for detection of diseasescancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarkercompound or body response useable for localization of diseasescancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarkercompound or body response useable for therapy of diseasescancer or other diseases related to genetic dysregulation
Classe 44
Medical services for prevention of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarkercompound or body response usable for these medical services; Medical services for detection of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarkercompound or body response usable for these medical services; Medical services for localization of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarkercompound or body response usable for these medical services; Medical services for therapy of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarkercompound or body response usable for these medical services; Medical services for prevention of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarkercompound or body response usable for these medical services; Medical services for detection of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarkercompound or body response usable for these medical services; Medical services for localization of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarkercompound or body response usable for these medical services; Medical services for therapy of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarkercompound or body response usable for these medical services
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
13/02/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/01/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/01/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/01/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/01/2024
ALIE
ASSIGNED TO LIE
09/01/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/08/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
07/07/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
07/07/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/04/2023
GNRT
NON-FINAL ACTION E-MAILED
10/04/2023
CNRT
SU - NON-FINAL ACTION - WRITTEN
10/04/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
24/02/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
23/02/2023
IUAF
USE AMENDMENT FILED
01/02/2023
EISU
TEAS STATEMENT OF USE RECEIVED
01/02/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
20/09/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
26/07/2022
PUBO
PUBLISHED FOR OPPOSITION
26/07/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/07/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
23/06/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
27/05/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/05/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/05/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
19/01/2022
GNRT
NON-FINAL ACTION E-MAILED
19/01/2022
CNRT
NON-FINAL ACTION WRITTEN
19/01/2022
DOCK
ASSIGNED TO EXAMINER
13/01/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/08/2021
NWAP
NEW APPLICATION ENTERED
13/05/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SYNTHETIC BIOPSY ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.